---
title: "Bright Minds Biosciences (DRUG) news: offering"
url: "https://aibio.space/companies/bright-minds-biosciences/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "DRUG offering news: Bright Minds Biosciences reports C$307,828,515 cash after public offering. Bright Minds Biosciences Inc. (CSE: DRUG), United States."
---

DRUG Bright Minds Biosciences Inc. CSE · United States

# Bright Minds Biosciences (DRUG) news DRUG offering news

Financings · 2026-08-17

## [Bright Minds Biosciences reports C$307,828,515 cash after public offering](https://aibio.space/news/bright-minds-biosciences-reports-c-307-828-515-cash-after-public/)

Cash and cash equivalents reached CAD 307,828,515 at June 30, 2026, after a January 2026 public offering at US$90 a share. Over the nine months the company used CAD 23,402,489 in operations and reported no revenue.

## Latest Bright Minds Biosciences news

1. 2025-08-26 Financings [Bright Minds Biosciences files $250,000,000 shelf with $100,000,000 ATM program](https://aibio.space/news/bright-minds-biosciences-files-250-000-000-shelf-100-000-000-atm/) Piper Sandler & Co. and Cantor Fitzgerald & Co. are the agents under an August 25, 2025 equity distribution agreement. The company's latest annual report shows cash used in operations of CAD 1.9 million for fiscal 2024.

## Bright Minds Biosciences at a glance

- **Ticker**: DRUG

- **Listing**: CSE

- **Country**: United States

- **Cash, Sep 30, 2024**: C$5.7 million

### Related companies

- [Syndax Pharmaceuticals](https://aibio.space/companies/syndax-pharmaceuticals/) NASDAQ: SNDX
- [MAIA Biotechnology](https://aibio.space/companies/maia-biotechnology/) AMEX: MAIA
- [Fate Therapeutics](https://aibio.space/companies/fate-therapeutics/) NASDAQ: FATE
- [NeoImmuneTech](https://aibio.space/companies/neoimmunetech/) KRX: 950220
- [Absci](https://aibio.space/companies/absci/) NASDAQ: ABSI
- [Arrowhead Pharmaceuticals](https://aibio.space/companies/arrowhead-pharmaceuticals/) NASDAQ: ARWR
- [Filana Therapeutics](https://aibio.space/companies/filana-therapeutics/) NASDAQ: FLNA
- [CalciMedica](https://aibio.space/companies/calcimedica/) NASDAQ: CALC

### Also on CSE

- [LIR Life Sciences](https://aibio.space/companies/lir-life-sciences/) SKNY
- [PreveCeutical Medical](https://aibio.space/companies/preveceutical-medical/) PREV
- [EGF Theramed Health](https://aibio.space/companies/egf-theramed-health/) TMED.X
- [Revive Therapeutics](https://aibio.space/companies/revive-therapeutics/) RVV
- [Pharmadrug](https://aibio.space/companies/pharmadrug/) PHRX
- [Rapid Dose Therapeutics](https://aibio.space/companies/rapid-dose-therapeutics/) DOSE

## Bright Minds Biosciences annual financials

| Line | FY ended Sep 30, 2024 | FY ended Sep 30, 2023 |
|---|---|---|
| Research and development | [C$1.2 million](https://www.sec.gov/Archives/edgar/data/1827401/000106299324021301/) | [C$5.0 million](https://www.sec.gov/Archives/edgar/data/1827401/000106299324021301/) |
| Net income (loss) | [-C$2.8 million](https://www.sec.gov/Archives/edgar/data/1827401/000106299324021301/) | [-C$7.4 million](https://www.sec.gov/Archives/edgar/data/1827401/000106299324021301/) |
| Cash from operations | [-C$1.9 million](https://www.sec.gov/Archives/edgar/data/1827401/000106299324021301/) | [-C$7.0 million](https://www.sec.gov/Archives/edgar/data/1827401/000106299324021301/) |
| Cash and equivalents | [C$5.7 million](https://www.sec.gov/Archives/edgar/data/1827401/000106299324021301/) | [C$6.7 million](https://www.sec.gov/Archives/edgar/data/1827401/000106299324021301/) |

Latest balance sheet, Sep 30, 2024 (20-F): cash and equivalents C$5.7 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Bright Minds Biosciences

Has Bright Minds Biosciences raised money recently?

Our latest story on this, dated Aug 17, 2026: "Bright Minds Biosciences reports C$307,828,515 cash after public offering". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/bright-minds-biosciences-reports-c-307-828-515-cash-after-public/).

What is the ticker symbol of Bright Minds Biosciences?

Bright Minds Biosciences Inc. trades under the ticker DRUG on CSE.

Where is Bright Minds Biosciences listed?

Bright Minds Biosciences Inc. is listed on CSE. Our directory also records these other listings: NASDAQ:DRUG; NEO:DRUG.

What is the SEC CIK of Bright Minds Biosciences?

The SEC Central Index Key (CIK) for Bright Minds Biosciences Inc. is 1827401. Its filings are on SEC EDGAR.

How many shares does Bright Minds Biosciences have outstanding?

4,524,087 shares as of 2024-09-30, per the cover page of its 20-F filed 2024-12-31.

Which country or territory is Bright Minds Biosciences listed under?

Our directory records Bright Minds Biosciences Inc. under United States.

What does Bright Minds Biosciences do?

Our directory classifies Bright Minds Biosciences Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Bright Minds Biosciences?

The ISIN recorded for Bright Minds Biosciences Inc. is CA10919W4056.

Does aibio.space cover Bright Minds Biosciences?

aibio.space lists Bright Minds Biosciences Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Bright Minds Biosciences incorporated?

SEC records list its state or country of incorporation as A1.

What is the latest Bright Minds Biosciences (DRUG) stock news?

Our latest story on Bright Minds Biosciences, dated Aug 17, 2026: "Bright Minds Biosciences reports C$307,828,515 cash after public offering". Cash and cash equivalents reached CAD 307,828,515 at June 30, 2026, after a January 2026 public offering at US$90 a share. Over the nine months the company used CAD 23,402,489 in operations and reported no revenue. [Source](https://aibio.space/news/bright-minds-biosciences-reports-c-307-828-515-cash-after-public/).

How long will Bright Minds Biosciences's cash last?

From our story of Aug 17, 2026: The statements are prepared on a going concern basis. [Source](https://aibio.space/news/bright-minds-biosciences-reports-c-307-828-515-cash-after-public/).

Is Bright Minds Biosciences a smaller reporting company?

SEC records list Bright Minds Biosciences Inc.'s filer category as: <br>Emerging growth company.

Where is Bright Minds Biosciences headquartered?

SEC records list its business address as 400 N ABERDEEN ST SUITE 900, CHICAGO, IL, 60642.

When does Bright Minds Biosciences's fiscal year end?

Bright Minds Biosciences Inc.'s fiscal year ends on September 30, per SEC records.

## Investor discussion: Bright Minds Biosciences

Members talk about Bright Minds Biosciences (DRUG). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Bright Minds Biosciences, newest first. Each line links the filing it comes from.

1. 2026-08-17 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1827401/000106299326004442/exhibit99-1.htm)
2. 2026-05-20 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1827401/000106299326002801/exhibit99-1.htm)
3. 2026-02-13 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1827401/000106299326000881/exhibit99-1.htm)
4. 2026-01-07 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1827401/000106299326000089/form424b5.htm)
5. 2025-08-26 Financings Set up an at-the-market program to sell shares over time. SEC Form F-3. [Source](https://www.sec.gov/Archives/edgar/data/1827401/000106299325014903/formf3.htm)
6. 2025-08-11 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1827401/000106299325014005/exhibit99-1.htm)
7. 2025-02-14 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1827401/000106299325002353/exhibit99-1.htm)
8. 2024-11-05 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1827401/000106299324018274/exhibit99-1.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open CSE:DRUG on TradingView](https://www.tradingview.com/symbols/CSE-DRUG/).

## SEC filings and registration

- **SEC name**: Bright Minds Biosciences Inc.

- **CIK**: 1827401

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: DRUG (Nasdaq)

- **State or country of incorporation**: A1

- **Fiscal year ends**: September 30

- **Filer category**: <br>Emerging growth company

- **Business address**: 400 N ABERDEEN ST SUITE 900, CHICAGO, IL, 60642

- **Phone**: 6474072515

- **Shares outstanding**: 4,524,087 as of 2024-09-30 (20-F filed 2024-12-31)

### Recent filings (8-K and 6-K are the company's own announcements)

- [6-K](https://www.sec.gov/Archives/edgar/data/1827401/000106299326005170/form6k.htm) filed 2026-10-02
- [6-K](https://www.sec.gov/Archives/edgar/data/1827401/000106299326005123/form6k.htm) filed 2026-10-01
- [6-K](https://www.sec.gov/Archives/edgar/data/1827401/000106299326004442/form6k.htm) filed 2026-08-17
- [6-K](https://www.sec.gov/Archives/edgar/data/1827401/000106299326003005/form6k.htm) filed 2026-06-03
- [6-K](https://www.sec.gov/Archives/edgar/data/1827401/000106299326002975/form6k.htm) filed 2026-06-02
- [6-K](https://www.sec.gov/Archives/edgar/data/1827401/000206075526000031/f6k-20260526.htm) filed 2026-05-28
- [6-K](https://www.sec.gov/Archives/edgar/data/1827401/000106299326002801/form6k.htm) filed 2026-05-20
- [6-K](https://www.sec.gov/Archives/edgar/data/1827401/000106299326000881/form6k.htm) filed 2026-02-13

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001827401), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Bright Minds Biosciences Inc. is a public biotech or pharmaceutical company listed on CSE under the ticker DRUG, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Bright Minds Biosciences Inc.

- **Ticker**: DRUG

- **Listing**: CSE

- **Country or territory**: United States

- **Business scope**: Biotechnology

- **ISIN**: CA10919W4056

- **Other listed symbols**: NASDAQ:DRUG; NEO:DRUG

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/CSE-DRUG/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/bright-minds-biosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Bright Minds Biosciences (DRUG) news: offering", 2026-10-31, https://aibio.space/companies/bright-minds-biosciences/